Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 20/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 20/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 20/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 15/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948706 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL2950831 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL2944873 | 0.89 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL2946329 | 0.89 | SLC6A2 (0.80) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL2951945 | 0.89 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL2951941 | 0.89 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL2953435 | 0.89 | SLC6A2 (0.79) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL2945366 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL2944537 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL2952360 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061774-B1 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | claimed |
| US-7754721-B2 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | claimed |
| EP-2061774-A2 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2009-05-27 | — | — | EP | claimed |
| WO-2008019971-A2 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | WO | claimed |
| CN-101501008-B | Arylpiperazine derivatives and uses thereof | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-07 | — | — | CN | disclosed |
| EP-2061774-B1 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| EP-2061774-B1 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-7754721-B2 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754721-B2 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754721-B2 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| CN-101501008-A | Arylpiperazine derivatives and uses thereof | HOFFMANN LA ROCHE (CH) | 2009-08-05 | — | — | CN | disclosed |
| EP-2061774-A2 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008019971-A2 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008019971-A2 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-02-21 | — | — | US | disclosed |
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-02-21 | — | — | US | disclosed |
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | CYP3A7, CYP3A5, HTR7 | SLC6A2 1508/4885SLC6A4 1438/4885SLC6A3 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.